Home|DSIJArticleDetail

This small-cap pharmaceutical stock soared 20 per cent! Time to buy?
This small-cap pharmaceutical stock soared 20 per cent! Time to buy?

This small-cap pharmaceutical stock soared 20 per cent! Time to buy?

The 20-DMA level lies at Rs 35 and a move above this level can attract strong buying interest. It has the potential to test the level of Rs 43, and thereafter, Rs 45 in the medium term. With rising volumes, the possibility is even more.

Rohit Kale Article rating: 3.8

This small-cap pharmaceutical company is actively engaged in the manufacturing of veterinary APIs. It manufactures bulk drugs for top established companies.

Stocks below Rs 100: Only buyers seen in these scrips on July 1
Stocks below Rs 100: Only buyers seen in these scrips on July 1

Stocks below Rs 100: Only buyers seen in these scrips on July 1

US stock futures fell on Friday morning after S&P 500 ended its worst first-half performance since 1970.   

Sayali Kotwal Article rating: 3.6

At noon on Friday, the headline equity indices, i.e. Sensex and Nifty 50 were trading lower as the global markets ended the second quarter of FY22.US stock futures fell on Friday morning after S&P 500 ended its worst first-half performance since 1970.   

This smallcap stock has surged 25 per cent in five trading sessions
This smallcap stock has surged 25 per cent in five trading sessions

This smallcap stock has surged 25 per cent in five trading sessions

It was up by 15 per cent in yesterday’s trading session alone.

Shashikant Singh Article rating: 4.9

 

Lasa Supergenerics, a vertically integrated company engaged in manufacturing veterinary and human APIs, animal feed ingredients is up by 25 per cent in the last few trading sessions. 

Lasa Supergenerics files another suit for permanent injunction against one of its competitors
Lasa Supergenerics files another suit for permanent injunction against one of its competitors

Lasa Supergenerics files another suit for permanent injunction against one of its competitors

Filing is aimed to prevent the unauthorised use and disclosure of the confidential information

Shashikant Singh Article rating: 5.0

The manufacturer of veterinary & human APIs, Lasa Supergenerics announced that it has filed suit for a permanent injunction against Lohita Lifescience Pvt Ltd and others restraining infringement of its patent. 

 

DSIJ MINDSHARE

Mkt Commentary14-May, 2024

Swing Trading14-May, 2024

Multibaggers14-May, 2024

Mindshare14-May, 2024

Multibaggers14-May, 2024

Knowledge

MF14-May, 2024

General13-May, 2024

General13-May, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList